

1 Network-based spreading of grey matter changes across different stages of psychosis

2
3 Sidhant Chopra^{1,2,3}, Ashlea Segal^{1,2}, Stuart Oldham^{1,2}, Alexander Holmes^{1,2}, Kristina
4 Sabaroedin^{1,2,12}, Edwina R. Orchard^{1,2,4}, Shona M. Francey^{5,6}, Brian O'Donoghue^{5,6}, Vanessa
5 Copley⁷, Barnaby Nelson^{5,6}, Jessica Graham^{5,6}, Lara Baldwin^{5,6}, Jeggan Tiego^{1,2}, Hok Pan
6 Yuen^{5,6}, Kelly Allott^{5,6}, Mario Alvarez-Jimenez^{5,6}, Susy Harrigan^{5,6,8}, Ben D. Fulcher⁹, Kevin
7 Aquino^{9,10}, Christos Pantelis^{7,13}, Stephen J Wood^{5,6,11}, Mark Bellgrove¹, Patrick McGorry^{5,6},
8 Alex Fornito^{1,2}

- 9
10
11
12 1. Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash
13 University, Clayton, Australia
14 2. Monash Biomedical Imaging, Monash University, Clayton, Australia
15 3. Department of Psychology, Yale University, New Haven, USA
16 4. Child Study Centre, Yale University, New Haven, USA
17 5. Orygen, Parkville, Australia
18 6. Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia
19 7. Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne
20 8. Centre for Mental Health, Melbourne School of Global and Population Health, The
21 University of Melbourne, Parkville, Australian
22 9. School of Physics, University of Sydney, New South Wales, Australia
23 10. Centre for Complex Systems, University of Sydney, New South Wales, Australia
24 11. School of Psychology, University of Birmingham, Edgbaston, UK
25 12. Departments of Radiology and Paediatrics, Hotchkiss Brain Institute and Alberta
26 Children's Hospital Research Institute, University of Calgary, Calgary, AB, Canada
27 13. NorthWestern Mental Health, Royal Melbourne Hospital & Western Hospital Sunshine,
28 St Albans, Victoria, Australia
29
30
31
32
33
34
35
36
37
38
39
40

41 Corresponding Author:

42 Sidhant Chopra (sidhant.chopra@yale.edu)
43 Yale University
44 Department of Psychology

45 **Key points (max 100 words)**

46

47 **Question** Are grey matter changes across the psychosis continuum constrained by brain
48 network architecture and are certain regions epicentres of volume loss?

49

50 **Findings** Across four independent samples spanning different stages of psychotic illness,
51 grey matter alterations are strongly constrained by the underlying architecture of the brain's
52 axonal pathways and the hippocampus is consistently identified as a putative source from
53 which volume-loss may spread to connected regions.

54

55 **Meaning** White matter fibres may act as conduits for the spread of pathology across all
56 stages of psychotic illness and medial temporal regions play a critical role in the origins of
57 grey matter reductions.

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76 **Abstract (350 words)**

77 **Importance:** Psychotic illness is associated with anatomically distributed grey matter reductions that
78 can worsen with illness progression, but the mechanisms underlying the specific spatial patterning of
79 these changes is unknown.

80
81 **Objective:** To test the hypothesis that brain network architecture constrains cross-sectional and
82 longitudinal grey matter alterations across different stages of psychotic illness and to identify whether
83 certain brain regions act as putative epicentres from which volume loss spreads.

84
85 **Design, Settings, Participants:** This study included 534 individuals from 4 cohorts, spanning early
86 and late stages of psychotic illness. Early-stage cohorts included patients with antipsychotic-naïve
87 first episode psychosis (N=59) and a group of medicated patients within 3 years of psychosis onset
88 (N=121). Late-stage cohorts comprised two independent samples of people with established
89 schizophrenia (N=136 in total). Each patient group had a corresponding matched control group
90 (N=218 in total). A further independent sample of healthy adults (N=346) was used to derive
91 representative structural and functional brain networks for modelling of network-based spreading
92 processes. We additionally examined longitudinal illness-related and antipsychotic-related grey matter
93 changes over 3 and 12 months using a triple-blind randomised placebo-control MRI study of the
94 antipsychotic-naïve patients. All data were collected between April 2008 and January 2020, and
95 analyses were performed between March 2021 and January 2023.

96
97 **Main Outcomes and Measures:** We used coordinated deformation models to predict the extent of
98 grey matter volume change in each of 332 parcellated areas by the volume changes observed in areas
99 to which they were structurally or functionally coupled. To identify putative epicentres of volume
100 loss, we used a network diffusion model to simulate the spread of pathology from different seed
101 regions. Correlations between predicted and empirical spatial patterns of grey matter volume
102 alterations were used to quantify model performance.

103
104 **Results:** In both early and late stages of illness, spatial patterns of cross-sectional volume differences
105 between patients and controls were more accurately predicted by coordinated deformation models
106 constrained by structural, rather than functional, network architecture ($.46 < r < .57$; $p < .001$).
107 The same model also robustly predicted longitudinal volume changes related to illness ($r > .52$; $p < .001$)
108 and antipsychotic exposure ($r > .50$; $p < .001$). Diffusion modelling consistently identified,
109 across all four datasets, the anterior hippocampus as a putative epicentre of pathological spread in
110 psychosis (*all* $p < .05$). Epicentres of longitudinal grey matter loss were apparent posteriorly early
111 in the illness and shifted anteriorly to prefrontal cortex with illness progression.

112
113 **Conclusion and Relevance:** Our findings highlight a robust and central role for white matter fibres
114 as conduits for the spread of pathology across different stages of psychotic illness, mirroring findings
115 reported in neurodegenerative conditions. The structural connectome thus represents a fundamental
116 constraint on brain changes in psychosis, regardless of whether these changes are caused by illness or
117 medication. Moreover, the anterior hippocampus represents a putative epicentre of early brain
118 pathology from which dysfunction may spread to affect connected areas.

119
120

121

122

123

124 **Introduction**

125 Psychotic disorders such as schizophrenia are characterised by anatomically distributed reductions in
126 grey-matter volume (GMV)¹⁻⁷, many of which show evidence of progression over time and across
127 different stages of illness⁸⁻¹⁴. Meta- and mega-analyses indicate that some of the most robust cross-
128 sectional GMV reductions are found in frontal, cingulate and temporal cortices, as well as medial
129 temporal lobe and thalamus^{3-7,15-17}, with longitudinal reductions identified in frontal, temporal and
130 parietal cortices^{9,11}. However, despite a large literature describing the location and nature of these
131 brain changes, the specific mechanisms that give rise to their characteristic spatial pattern remain
132 unknown.

133
134 The human brain is an intricate network of functionally specialised regions linked by a complex web
135 of axonal fibres, referred to as a connectome¹⁸. These fibres enable the widespread coordination of
136 neuronal dynamics and the transport of trophic and other biological molecules throughout the brain.
137 They can also act as conduits for the spread of pathology, such that illness processes originating in
138 one area can propagate to affect distributed systems via multiple mechanisms^{19,20}. This principle has
139 been powerfully demonstrated in dementia, where GMV reductions in different neurodegenerative
140 conditions have been shown to spread through the brain in a way that is constrained by the underlying
141 architecture of the brain's white-matter pathways²¹⁻²⁴.

142
143 Recent work suggests that a network-based spreading process may also be involved in psychosis.
144 Cross-sectional grey-matter reductions in patients correlate with increased fractional anisotropy in
145 regionally adjacent white matter²⁵, are often correlated across spatially distributed regions²⁶⁻²⁸, and
146 correspond with normative connectome organisation^{29,30}. In recent work, Shafiei, et al.³¹ developed a
147 coordinated-deformation model (CDM) in a sample of people with established schizophrenia that
148 predicted the level of cross-sectional GMV reduction in an area based on the average reductions
149 observed in other areas to which it was structurally connected.

150
151 Together, these findings support the hypothesis that the spatial patterning of GMV loss in psychotic
152 illness is constrained by connectome architecture. However, the few studies addressing this question
153 have been cross-sectional and only examined patients with chronic illness, precluding an opportunity
154 to track how coordinated grey-matter changes evolve through time and across illness stages. It thus
155 remains unclear whether longitudinal GMV changes are actually constrained by brain network
156 architecture, as would be expected for a network-based spreading process. Moreover, the reliance on
157 samples of patients taking antipsychotic medication makes it difficult to determine whether coupled
158 grey-matter changes are driven by treatments for the illness or the illness process itself.

159
160 Here, we used multiple cohorts spanning different stages of psychosis to comprehensively evaluate
161 network constraints on cross-sectional and longitudinal GMV changes. Specifically, we evaluated the
162 capacity of different CDM variants, constrained by distinct aspects of connectome structure or
163 function, to model cross-sectional GMV differences in two samples of patients at early illness stages
164 and two samples of patients at later stages, allowing for independent replication of our findings at
165 each stage. The early-stage samples comprised a group of antipsychotic-naïve first episode psychosis
166 patients and a group of medicated patients within 3 years of illness onset. The late-stage samples
167 comprised two independent samples of people with established schizophrenia. We additionally
168 leveraged longitudinal data acquired within the context of a longitudinal, randomised placebo-
169 controlled study in the antipsychotic-naïve FEP group^{32,33} to evaluate the degree to which the CDMs
170 predicted longitudinal GMV changes attributable to either antipsychotic medication or the illness

171 process itself, as observed over 3- and 12-month intervals. We then used a network-based diffusion
 172 model to simulate the dynamic progression of GMV loss from different seed areas to determine
 173 whether specific brain regions act as putative sources or epicentres of network-based spread. This
 174 approach thus allowed us to robustly investigate the degree to which brain network architecture
 175 constrains a diverse array of cross-sectional and longitudinal GMV pathology across different stages
 176 of psychosis and to identify possible focal points of early brain volume loss.
 177

178 **Methods**

179 **Sample characteristics**

180 This study used data from four independent datasets sampling different stages of the psychotic-illness
 181 continuum: the STAGES clinical trial^{13,33} (first episode psychosis; FEP), Human Connectome Project
 182 Early Psychosis³⁴ (early psychosis; EP), BrainGluSch³⁵ (schizophrenia; SCZ-BGS), and COBRE³⁶
 183 (schizophrenia; SCZ-COBRE). Hereafter, these cohorts will be referred to as FEP, EP, SCZ-BGS and
 184 SCZ-COBRE, respectively. We also derived representative structural and functional connectomes
 185 using a large independent healthy control sample. The final number of included subjects,
 186 demographic and diagnostic characteristics are described in Table 1 and additional details about each
 187 dataset are provided in the Supplement 1A.
 188
 189
 190

	First episode psychosis (FEP) N=86			Early psychosis (EP) N=178		Schizophrenia (SCZ-COBRE) N=138		Schizophrenia (SCZ-BGS) N=132		Independent healthy control N=356
	Placebo	Antipsychotic	Matched control	Patient	Matched control	Patient	Matched control	Patient	Matched control	Independent healthy control
N	Bl =30; 3m=21; 12m=22	Bl =29; 3m = 20; 12m =14	Bl =27; 3m = 21; 12m =21	121	57	66	72	70	62	356
Baseline age, years ± SD	18.8±2.7	19.5±2.9	21.9±1.9	23.3± 3.9	23.4±3.9	38.0±14.1	35.9±11.7	36.6±13.4	38.22±12.4	23.7±5.4
Baseline Females, N (%)	14 (46.6)	13 (44.8)	17 (62.9)	47 (38.9)	30 (35.0)	12 (8.8)	23 (31.9)	10 (14.2)	14 (22.6)	198 (55.6)
Diagnosis, N										
Major depression w/ psychosis	7	5	-	5	-	0	-	0	-	-
Schizophreniform disorder	5	5	-	8	-	0	-	0	-	-
Psychotic disorder NOS	8	7	-	0	-	0	-	0	-	-
Substance-induced psychotic disorder	4	2	-	0	-	0	-	0	-	-
Delusional disorder	1	4	-	0	-	0	-	0	-	-
Schizoaffective disorder				13	-	6	-	0	-	-
Schizophrenia	5	5	-	61	-	60	-	70	-	-
Bipolar Disorder w/ psychosis	0	0	-	25	-	0	-	0	-	-
Missing diagnosis	0	1	-	0	-	0	-	0	-	-
Illness Duration (Years)	<0.5	<0.5	-	1.8 (1.4)	-	16.0 (12.2)	-	18.2 (12.9)	-	-

Symptom severity, scale; mean \pm SD	Baseline BPRS Total; 59.4 \pm 9.64	Baseline BPRS Total; 55.8 \pm 10.10	PANSS Total; 49.7 \pm 11.0	PANSS Total; 58.4 \pm 13.6	PANSS Total; 60.7 \pm 16.9
Functional outcome, scale; mean \pm SD	Baseline SOFAS; 52.9 \pm 14.0	Baseline SOFAS; 51.7 \pm 10.6	GAF; 66.4 \pm 16.6	CGI; 3.7 \pm 0.6	CGI; 3.9 \pm 0.8

Table 1 - Sample characteristics of included datasets.

Abbreviations: NOS = not otherwise specified; BPRS = Brief Psychiatric Rating Scale version 4; SOFAS = Social and Occupational Functioning Assessment Scale; BI = baseline, 3m = 3-months, 12m = 12months; PANSS = Positive and Negative Syndrome Scale, GAF = Global Assessment of Functioning Scale (average of the social and occupational rating items); CGI: The Clinical Global Impressions Scale.

Structural MRI processing

Acquisition parameters for structural MRI can be found in Supplement1B. Prior to processing, raw T1w scans were visually examined for artefacts and then subjected to an automated quality control procedure³⁷. In the FEP, EP, SCZ-BGS and SCZ-COBRE datasets, three, eight, six and four patient scans did not pass image quality control, respectively, and were excluded due to artefacts (see Supplement). The remaining scans were processed using the deformation-based morphometry (DBM) pipeline of the Computational Anatomy Toolbox (version r1113)³⁸ for the Statistical Parametric Mapping 12³⁹ software running in MATLAB version 2019a (details in the Supplement1C). We used DBM to quantify volume changes because it does not require tissue segmentation, requires less spatial smoothing⁴⁰ than voxel-based morphometry (VBM) and to be comparable to previous work^{24,31}. However, we replicated our primary findings using VBM (see *Robustness analyses*).

Quantifying cross-sectional and longitudinal grey matter changes in patients

To map spatial patterns of group-level cross-sectional and longitudinal volume change, we used a robust marginal model implemented in the Sandwich Estimator Toolbox⁴¹, which combines ordinary least squares estimates of parameters of interest with estimates of variance/covariance based on a robust sandwich estimator, thus accounting for within-subject correlations in longitudinal studies. This method is asymptotically robust to misspecification of the covariance model and does not depend on the assumptions of common longitudinal variance structure across the whole brain. All contrasts were adjusted for age, sex, and handedness, with site additionally included for the EP dataset.

We conducted cross-sectional contrasts in each of the four patient datasets to capture cross-sectional GMV differences between patients and controls (Fig1A). Longitudinal GMV changes were mapped in the FEP dataset (Fig1A) to isolate: (1) illness-related change over time, by comparing GMV changes over time in the placebo group to matched healthy controls; and (2) antipsychotic-related changes over time, which compared GMV changes in the medication group to both the placebo group and matched healthy controls (see also¹³). Longitudinal contrasts were assessed from baseline to 3 months and baseline to 12 months, with a linear contrast being used for the latter. Contrasts were specified such that positive values in the resulting voxel-wise *t*-statistic maps indicate lower volume in patients compared to controls at cross-sectional contrast, and a greater longitudinal GMV decline in patients compared to controls in the longitudinal contrasts. The *t*-statistics were converted to *z*-scores, and we applied the CDM to unthresholded *z*-maps encoding regional GMV changes, as we are interested in capturing the spatial patterning of GMV differences across the entire brain, not just the changes which survive a statistical threshold. Renderings of the unthresholded *t*-maps can be found in Fig1A-C and Fig2A-B. FDR-corrected and uncorrected voxel-level *t*-statistic maps for each contrast are provided in the Supplements1F-1G.


235 **Brain Parcellation**

236 To relate grey-matter alterations to connectome architecture, we parcellated the brain into 300 discrete
 237 cortical regions of approximately equal size⁴², in addition to 32 subcortical areas⁴³, using previously
 238 validated atlases. The volume change for each region was estimated as the mean z -statistic of all
 239 voxels corresponding to that region. The regions comprise the nodes of a network, which can then be
 240 directly related to measures of inter-regional SC and FC.

241
 242 **Healthy reference connectomes**

243 We derived a group-level healthy structural connectome from diffusion-weighted imaging (DWI) data
 244 from an independent sample of 356 adults (Fig1B; Table 1), which served as a reference connectome
 245 for computational modelling. Acquisition parameters and detailed overview of DWI processing and
 246 optimisation can be found in Supplement1D. This procedure resulted in a single 332×332 weighted
 247 group-average SC matrix.

248
 249 We also derived a group-level healthy functional connectome from resting-state fMRI data acquired
 250 in the same independent sample of adults (Fig1B). Acquisition parameters for functional MRI and
 251 detailed information on fMRI processing can be found in Supplement1E. Given ongoing controversy
 252 around the application of global signal regression^{44,45}, we evaluated how this step affected our
 253 findings (see *Robustness analyses*). After processing and denoising, we computed a whole-brain
 254 332×332 FC matrix for each subject using pair-wise Pearson correlations between the timeseries of
 255 each of the 332 regions and finally took a mean FC matrix across the sample.
 256



257
 258 **Fig1. - Analysis workflow for the Coordinated Deformation Model.** (A) We derived voxel-wise GMV
 259 estimates using Deformation-based morphometry (DBM). Five separate contrasts were specified using a robust
 260 marginal model to infer baseline GMV differences and longitudinal GMV changes associated with illness and
 261 antipsychotic medication at 3 months and 12 months. (B) The contrast statistics were mapped to a brain
 262 parcellation comprising 332 regions, and diffusion and functional MRI data from an independent healthy sample
 263 were used to generate sample-averaged functional coupling (FC) and structural connectivity (SC) matrices.
 264 These matrices were used to model average volume changes in structurally connected neighbours. Under the
 265 CDM, the predicted deformation of a node, \hat{d}_i , is modelled as a weighted sum of the deformation values

266 observed its structurally connected neighbours (shown as light blue nodes in the example graphs). The weights
267 are given by the adjacency matrix, A_{ij} . Three different matrices were used, yielding three CDM variants; (1) A
268 model denoted as CDM_{SC} , in which $A_{ij} = 1$ if two regions share a connection and $A_{ij} = 0$ otherwise; (2) a
269 model denoted as CDM_{SCw} in which the elements of A_{ij} correspond precisely to the weighted SC matrix, such
270 that the contribution of each neighbour is weighted by the strength of its structural connectivity to the index
271 node; and (3) a model denoted CDM_{FCw} , in which the elements of A_{ij} correspond precisely to the weighted FC
272 matrix, such that the contribution of each neighbour is weighted by its FC with the index node. (C) Model
273 performance was evaluated using the Pearson correlation between regional estimates of observed and predicted
274 GMV differences. (D) We also compared model performance to three benchmark null models accounting for
275 spatial autocorrelations in the deformation maps ($Null_{smash}$ and $Null_{spin}$) and basic topological properties of the
276 connectome ($Null_{rewire}$; see *CDM evaluation*).

277

278 ***Coordinated Deformation Model (CDM) – Network Constraints***

279 We evaluated network constraints on cross-sectional and longitudinal GMV changes using the CDM
280 introduced by Shafiei, et al.³¹. The model is given by

281

$$282 \hat{d}_i = \frac{1}{N_i} \sum_{j=1, j \neq i}^{N_i} A_{ij} d_j,$$

283

284 where \hat{d}_i is the predicted GMV change in node i , N_i is the number of structurally connected
285 neighbours of i , d_j is the deformation observed in the j -th neighbour of node i , and A_{ij} defines the
286 connectivity between nodes i and j .

287

288 Three different matrices were substituted for A_{ij} , yielding three variants of the CDM (Fig1B). For the
289 first model, denoted CDM_{SC} , $A_{ij}=1$ if nodes i and j are connected in the group-average SC matrix and
290 zero otherwise. Therefore, all j structurally connected neighbours make an equal contribution to
291 predicting the extent of deformation observed in node i .

292

293 For the second and third models, denoted CDM_{SCw} and CDM_{FCw} , A_{ij} corresponded to the weighted
294 SC or FC matrices, respectively. Therefore, under these models, the contributions of node i 's
295 neighbours were weighted by either inter-regional SC (CDM_{SCw}) or FC (CDM_{FCw}) estimates, such that
296 neighbours of node i with a more strongly weighted connection made a stronger contribution to
297 predicting node i 's volume change (Fig1B). In all models, only edges that had a corresponding
298 structural connection were included and SC and FC edge weights were taken from the healthy
299 reference connectome, unless otherwise specified.

300

301 ***CDM evaluation***

302 Model performance was evaluated using the product-moment correlation (r) between region-wise
303 estimates of observed and predicted deformation (Fig1C). We also compared the performance of the
304 CDM_{SC} , CDM_{SCw} and CDM_{FCw} models to three benchmark null models. The first (Fig1D; $Null_{smash}$)
305 and second (Fig1D; $Null_{spin}$) null models evaluated whether the observed findings were specific to the
306 empirically observed pattern of grey-matter deformations or were a generic property of the intrinsic
307 spatial correlation structure of the deformation maps. The third null model (Fig1D; $Null_{rewire}$) tests the
308 hypothesis that any network-based prediction of local grey-matter change is specific to the actual
309 topology of the connectome itself and cannot be explained by basic network properties, such as
310 regional variations in node degree or the spatial dependence of inter-regional connectivity⁴⁶. Further
311 details about benchmark null models can be found in the Supplement1H.

312

313 ***Network Diffusion Model (NDM) – Epicentre Identification***

314 The CDM evaluates the degree to which spatial patterns of GMV change are shaped by connectome
315 properties. A close coupling between GMV change and network architecture implies that volume loss
316 spreads through the connectome, but the CDM offers limited insight into the dynamics of the
317 spreading process, nor is it able to identify regions from which the spreading may initiate. We
318 therefore used a NDM to directly test whether GMV loss spreads through the brain via a process of
319 diffusion and whether certain brain regions act as sources, or epicentres, of pathological spread
320 through the brain (Fig4)⁴⁷. The NDM simulates the dynamic spread of pathology between the nodes
321 of a weighted network via a process of diffusion (Fig4A), defined as

322

323

$$f(t) = e^{-\alpha H t} f_0,$$

324

325 where t is the model diffusion time, which has arbitrary units (a.u.), and $f(t)$ is a vector
326 characterizing the amount of diffusion in each region at time t . The strength of the diffusion process
327 is controlled by a constant (α) and H is the Laplacian of the weighted SC matrix. f_0 represents the
328 initial distribution of pathology. We repeatedly initialized the model using each of the 332 regions as
329 the starting seed, such that the initial state was set to 1 for the seed region, and 0 for all other regions.
330 At each initialization, using a constant of $\alpha = 1$, the NDM was used to estimate the diffusion at all
331 other regions at time $t = 0$ to 50. In this way, we were able to determine whether a diffusion process
332 seeded from each region resulted in a spatial distribution of volume loss that matched the empirically
333 observed patterns. Further information about the NDM can be found in the Supplement1I.

334

335 ***NDM evaluation***

336 Consistent with prior work^{47,48}, model performance was evaluated as the Pearson correlation between
337 the predicted diffusion and observed volume abnormalities at each time step and for each seed, with
338 the maximum correlation (Fig4A; r_{max}) across all time steps being retained. The observed regional t -
339 statistics were rescaled to a more interpretable non-negative quantity via a log-transformation,
340 yielding values in the range $[0,1]$ ⁴⁷⁻⁴⁹. The seed region was excluded when correlating predicted and
341 observed volume abnormalities to ensure that our analysis was not influenced by large volume
342 abnormalities in the seeds. The performance of the NDM in capturing the empirical maps of GMV
343 change was compared to its performance in capturing surrogate maps generated using the Null_{smash} and
344 Null_{rewire} benchmark models (Fig4A). The Null_{spin} benchmark was not used to evaluate the NDM as it
345 does not include subcortical regions. Further details about benchmark null models used to evaluate the
346 NDM can be found in the Supplement1I.

347

348 To aid comparison with previous research³¹, we also implemented a data-driven approach to epicentre
349 identification that defines epicentres as regions with high volume loss that are also connected to other
350 regions with high volume loss (FigS2; see Supplement1J for details). The spatial locations of
351 epicentres identified by this approach closely aligned with the results of the NDM epicentre analysis.


352

353 **Results**

354 ***Structural connectivity shapes cross-sectional grey matter differences across illness stages***

355 We first evaluated the performance of the three CDMs in capturing cross-sectional differences in
356 regional GMV. In all datasets, the CDM_{SCw} model yielded more accurate predictions of cross-
357 sectional empirical GMV case-control differences ($.46 < r < .57$; Fig2E-H) when compared with

358 the CDM_{SC} and CDM_{FCw} models (*all* $r < .35$; Fig2E-H). For all data sets, the performance of the
 359 CDM_{SCw} was also significantly better than all three benchmark models (*all* $p < 0.01$). The CDM_{SC}
 360 and CDM_{FCw} generally did not surpass the performance of the benchmark models.
 361
 362



363
 364 **Fig2. – Baseline and longitudinal illness-related GMV changes are constrained by connectome**
 365 **anatomy.** (A-D) The contrast statistics for four cross-sectional contrasts mapped to a brain
 366 parcellation comprising 332 regions. (E-H) Performance of the equally weighted (CDM_{SC}), structural
 367 connectivity-weighted (CDM_{SCw}), and functional coupling-weighted (CDM_{FCw}) models relative to the
 368 Null_{smash}, Null_{spin}, and Null_{rewire} benchmarks. Black circles indicate the observed rank correlations
 369 between predicted and actual regional deformation values for each model at each timepoint, with red
 370 borders indicating statistical significance. Note that the observed value used for comparison against
 371 the Null_{spin} models is different because the subcortex was excluded. (I-L) Scatterplots of the
 372 association between observed and predicted regional volume deformation values for the best
 373 performing CDM_{SCw} model at each timepoint.

374
 375 **Structural connectivity shapes longitudinal GMV changes**


376 Having robustly demonstrated that cross-sectional grey matter differences at different illness stages
 377 are related to connectome structure, we next tested the implicit assumption of the CDM—that
 378 longitudinal GMV changes spread across axonal pathways—by considering longitudinal illness-
 379 related and medication-related changes in the FEP sample.
 380

381 Predictions of the CDM_{SCw} model for illness-related grey matter changes at 3 and 12 months were
 382 correlated with empirical changes at $r = .58$ (Fig3E) and $r = .52$ (Fig3F), respectively, and both
 383 were significantly better than all three benchmark models (*all* $p < .001$). By comparison, correlations

384 for the CDM_{SC} and CDM_{FCw} did not exceed $r = .38$ and only showed significantly better performance
 385 compared to the $Null_{smash}$ and the $Null_{spin}$ at 3 months, but not connectome benchmarks (all $p >$
 386 0.05 ; Fig2E – F).

387

388 Predictions of the CDM_{SCw} model for antipsychotic-related grey-matter changes were correlated with
 389 the empirical maps at $r = .51$ (Fig3E) for 3 months and $r = .25$ (Fig3F) for 12 months. This
 390 association was statistically significant when compared to all three null models (all $p < 0.01$; Fig3C-
 391 D). Associations at 3 months and 12 months were smaller for the CDM_{SC} ($r = .34$ and $r = .24$,
 392 respectively) and CDM_{FCw} models ($r = .38$ and $r = .31$, respectively). At 3 months, the CDM_{SC} and
 393 CDM_{FCw} models only showed significantly better performance than the $Null_{smash}$ and $Null_{spin}$ ($p <$
 394 $.01$) benchmarks. At 12 months, the CDM_{SC} model showed significantly better performance than the
 395 $Null_{smash}$ and $Null_{rewire}$ benchmarks and the CDM_{SC} model showed significantly better performance
 396 than the $Null_{smash}$ and $Null_{spin}$ benchmarks ($p < .05$). Thus, connectome structure represents a generic
 397 constraint on both illness-related and medication-related longitudinal GMV changes in psychosis.
 398



399

400 **Fig3 – Longitudinal illness-related and antipsychotic-related GMV changes are constrained by**
 401 **connectome anatomy.** (A-D) The contrast statistics for illness-related and antipsychotic-related
 402 contrasts mapped to a brain parcellation comprising 332 regions. (E-H) Performance of the equally
 403 weighted (CDM_{SC}), structural connectivity-weighted (CDM_{SCw}) and functional coupling-weighted
 404 (CDM_{FCw}) models relative to the $Null_{smash}$, $Null_{spin}$, and $Null_{rewire}$ benchmarks. Black circles indicate
 405 the observed rank correlations between predicted and actual regional deformation values for each
 406 model at each timepoint, with red borders indicating statistical significance. Note that the observed
 407 value used for comparison against the $Null_{spin}$ models is different because the subcortex was excluded.
 408 (I-L) Scatterplots of the association between observed and predicted regional deformation values for
 409 the best performing CDM_{SCw} model at each timepoint.

410

411 ***Epicentres of grey matter volume loss***

412 We next used the NDM to simulate the dynamic spread of GMV loss from each individual brain
413 region. Results using the Null_{smash} benchmark are presented below (Fig4C-J) and results using the
414 Null_{rewire} benchmark are presented in the Supplement (FigS4). Across all cross-sectional comparisons,
415 medial temporal lobe regions emerged as statistically significant epicentres (Fig4C-F). In particular,
416 the anterior hippocampus was consistently implicated across all datasets ($p < 0.05$), surviving
417 multiple comparison correction ($p_{FWE} < 0.05$) in the two schizophrenia samples. In the FEP dataset,
418 additional epicentres were identified in bilateral occipital and temporal cortex, as well as
419 hippocampus, amygdala, and posterior thalamic regions (Fig4C). In the EP dataset, additional
420 epicentres were identified in temporal and posterior cingulate cortex, (Fig4D). In both schizophrenia
421 samples, additional epicentres were identified in temporal cortex, amygdala, and posterior thalamic
422 regions (Fig4E-F). Consistent results were obtained using the Null_{rewire} benchmark (FigS4).


423

424 In the FEP sample, epicentres of longitudinal illness-related loss were identified in medial frontal
425 regions at 3 months and progressed to include much of the frontal cortex, as well as striatal and
426 thalamic regions, by 12 months (Fig4G-H). Comparison with the connectome-based null benchmarks
427 were more conservative, but also implicated prefrontal regions (FigS4).

428

429 Epicentres of longitudinal antipsychotic-related GMV loss in FEP were identified in sensorimotor,
430 cingulate and insula cortices, as well as thalamic and amygdala regions at 3 months, with the same
431 cortical epicentres also identified at 12 months (Fig4I-J). These results were largely consistent when
432 using the Null_{rewire} models (FigS4). Scatter plots of observed and predicted volume abnormalities for
433 all contrasts are provided in the Supplement (FigS3).

434



435

436

437 **Fig4 – Regional epicentres of grey matter loss.** (A) Epicentres were defined as potential sources of pathological
 438 volume loss from which GMV reductions spread (Blue) to affect structurally connected areas. To identify such
 439 regions, we simulated a spreading process using a Network Diffusion Model (NDM), (B) using each of the 332
 440 parcellated regions as a seed, we retained the maximum correlation between the simulated and observed GMV
 441 abnormalities (r_{max}). For each contrast, we then compared r_{max} values for each region to distribution of
 442 r_{max} values from two benchmark null models accounting for spatial autocorrelations in the deformation maps
 443 (Null_{smash}) and basic topological properties of the connectome (see Model evaluation (NDM)). Regional
 444 epicentres with significantly greater r_{max} than a spatially constrained null model (Orange = $p < 0.05$; Red =
 445 $p_{FWE} < 0.05$) are shown for cross-sectional (C-F) and longitudinal (G-J) effects. Results using Null_{rewire}
 446 benchmark models, and scatter plots of observed and predicted volume abnormalities are provided in
 Supplement (FigS3).

447

448

449

450

451

452

453

454

455

456

457

458 ***Robustness analyses***

459 The magnitude and pattern of results remained consistent with our original findings after only
460 considering individuals diagnosed with schizophrenia or schizophreniform disorder, indicating that
461 diagnostic heterogeneity of the FEP and EP samples did not substantially impact our findings (FigS6).
462

463 To ensure that the wide-spread changes in white-matter integrity often reported in patients⁵⁰⁻⁵³ did not
464 affect model estimates of the network-based spread of pathology, we replicated our findings using
465 structural and functional connectomes derived from the FEP patient sample rather than the
466 independent healthy control sample (FigS7). We also replicated the results using a representative
467 structural connectome derived from the healthy control sample in the FEP study (FigS8).
468

469 Finally, our findings were consistent when using VBM instead of DBM (FigS9), and when applying
470 global signal regression (GSR) on subject-level FC matrices before computing the group average FC
471 matrix (FigS10).

472 **Discussion**

473 The mechanisms driving spatially patterned grey matter volume (GMV) changes in psychotic illness
474 have thus far been unclear. We have used a simple coordinated deformation model (CDM) to confirm
475 that, across both early and later stages of illness, cross-sectional GMV changes are shaped by the
476 topology and strength of structural, but not functional, connectivity between brain regions. We further
477 found that both illness-related and antipsychotic-related longitudinal changes are constrained by
478 structural connectivity, indicating that the temporal evolution of brain changes in the illness is also
479 constrained by the brain's axonal pathways. Moreover, using a network diffusion model (NDM) to
480 simulate the spread of pathology from different brain regions, we identified the anterior hippocampus
481 as a putative epicentre of volume loss across all illness stages and further showed a dynamic
482 progression of epicentres of dynamic grey matter loss from posterior to anterior areas, suggesting that
483 the pathological burden within temporal and prefrontal systems increases as the illness progresses.
484

485 ***Structural connectivity constrains GMV changes in psychotic illness***

486 The strength and topology of the structural connectome shaped the spatial pattern of volume
487 abnormalities across both early and late stages of illness. Our findings in established schizophrenia
488 align with previous research using the CDM to show that structural connectivity constrains the spatial
489 patterning of cross-sectional GMV differences in people with established schizophrenia³¹. This earlier
490 result was observed using the CDM_{SC} model considered here. In our analysis, we found that the
491 strength of structural connectivity between regions modulates coupled GMV differences within
492 structurally connected neighbourhoods, given that the CDM_{SCw} showed clearly superior performance
493 to the CDM_{SC} and CDM_{FCw} models in all datasets. This result indicates that GMV differences are
494 more tightly coupled between areas with high structural connectivity. Critically, our findings show
495 that network constraints on cross-sectional GMV differences cannot be explained by antipsychotic
496 medication, as our FEP sample was antipsychotic-naïve at the baseline scan. Moving beyond cross-
497 sectional differences, our longitudinal analysis further demonstrates that both illness-related and
498 antipsychotic-related changes in GMV are constrained by connectome architecture.
499

500 These results are in line with a spreading process in which pathology propagates across axonal
501 connections. The precise mechanisms driving this process remain unclear. While there is limited
502 evidence for visible deposits of aggregated pathological proteins in psychotic illness, more subtle
503 changes in protein homeostasis⁵⁴ may occur in subsets of patients and spread to synaptically

504 connected distant brain regions⁵⁵. Alternatively, and given the commonly reported finding of
505 functional brain alterations in psychotic disorders, dysfunction of one region may trigger abnormal
506 activity in connected sites which, over time, may trigger structural changes as a result of aberrant
507 neurotransmission or a loss of trophic support²⁰. This process may be exacerbated by a breakdown of
508 white-matter fibre integrity, which may further disrupt the inter-regional transport of trophic factors.
509 Accordingly, widespread but subtle alterations in white matter have been repeatedly demonstrated in
510 psychosis populations⁵⁶, are anticorrelated with cortical thickness²⁵, and may predate the transition to
511 psychosis in high-risk samples^{50,51}. Although our analyses suggest that using a structural connectome
512 derived from a patient sample did not change the overall pattern of our findings, further work may
513 investigate how coordinated GMV changes interact with white-matter pathology in patients.

514

515 An alternative explanation for our findings is that regions sharing a strong anatomical connection
516 have a more similar molecular and cytoarchitectonic profile, resulting in a shared vulnerability to
517 illness- or treatment-related changes⁵⁷⁻⁶⁰. Future research should examine associations between the
518 strength of structural connectivity and shared molecular features such as receptor profiles, gene
519 expression, and synaptic density in patient populations.

520

521 ***The medial temporal lobe as an epicentre of grey matter differences in psychosis***

522

523 Our NDM analysis indicated that the medial temporal lobe, and the anterior hippocampus in
524 particular, is a putative source of GMV loss in psychosis. The hippocampus has repeatedly been
525 implicated in the pathogenesis of psychosis. It has been linked to early neurodevelopmental
526 aberrations⁶¹⁻⁶³ and often shows lower levels of mRNA and protein markers of synaptic and dendritic
527 function post-mortem^{64,65}. Recent *in vivo* PET imaging studies have also identified a loss of synaptic
528 vesicle proteins^{66,67}. Multiple animal models and human studies have indicated that a primary
529 dysfunction occurring within the hippocampus^{68,69}, such as a loss of pyramidal cell inhibition, results
530 in downstream brain abnormalities including disinhibition of striatal dopamine release^{70,71} and
531 aberrant corticostriothalamic functioning⁷². Other evidence suggests that dysregulation of glutamate
532 neurotransmission beginning in the CA1 region^{73,74} initiates the transition to psychotic illness and
533 eventuates in an atrophic process in which neuropil and interneurons are reduced in other medial
534 temporal and structurally connected regions.

535

536 ***Regional epicentres of longitudinal grey matter change dynamically evolve with illness progression***

537

538 While the hippocampus was robustly implicated as a putative epicentre for cross-sectional GMV
539 differences at different illness stages, our analysis of longitudinal changes in the FEP group identified
540 putative epicentres in striatal and prefrontal areas. This contrasts the largely posterior focus of cortical
541 epicentres for baseline GMV differences in this group, suggesting that the most pronounced
542 longitudinal GMV changes occurring early in the illness affect the prefrontal cortex, which aligns
543 with the greater involvement of striatal and prefrontal areas at the 12 compared to 3-month follow-up.
544 These findings also accord with longitudinal studies in early-onset schizophrenia demonstrating a
545 dynamic wave of volume contraction progressing from posterior to anterior regions,^{75,76} and other
546 evidence of pronounced prefrontal GMV reductions in the earliest stages of illness^{8,77-83}, which may
547 reflect an exaggeration of normal neurodevelopmental processes^{84,85}. Notably, these regional
548 epicentres of illness-related GMV loss were distinct from epicentres of antipsychotic-related GMV
549 loss, which were identified in somatosensory, motor, and posterior cingulate regions.

550

551 ***Limitations and conclusions***

552 Our findings depend on group-level summary metrics of brain volume and may not be representative
553 of volume changes at the individual patient level, which can show substantial heterogeneity⁸⁶⁻⁸⁸.
554 Subsequent work could look at whether using individual-level measures of brain volume and
555 connectivity can improve model predictions. Moreover, given the complexity and practical challenges
556 of conducting a prospective triple-blind randomised control MRI study in antipsychotic-naïve
557 patients, the sample size of the longitudinal FEP sample is small (see also^{89,90} for a discussion of the
558 representativeness of this sample). Replication of our longitudinal analysis in larger samples is thus
559 warranted.

560

561 In summary, we identify a robust and central role for axonal connectivity as a conduit for the spread
562 of pathology across early and late stages of psychotic illness, mirroring findings reported in
563 neurodegenerative conditions. Our findings also align with animal models to suggest that medial
564 temporal regions may play a critical role in the origins of brain dysfunction and indicate that the
565 structural connectome represents a fundamental constraint on brain changes in psychosis, regardless
566 of whether they are caused by illness or medication.

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583 **Disclosures/Conflict of Interest**

584 SF, KA, MAJ and AF reported receiving grants from the Australian National Health & Medical
585 Research Council (NHMRC) and Australian Research Council (ARC) during the conduct of the
586 study. CP reported receiving grants from the Australian NHMRC and from the Lundbeck Foundation
587 and personal fees from Lundbeck Australia Pty Ltd Advisory Board for talks presented at educational
588 meetings organized by Lundbeck. PM reported receiving grants from the Australian NHMRC, the
589 Colonial Foundation, the National Alliance for Research on Schizophrenia and Depression, the
590 Stanley Foundation, the National Institutes of Health, Wellcome Trust, the Australian and Victorian
591 governments, and Janssen-Cilag (unrestricted investigator-initiated grant) during the conduct of the
592 study; past unrestricted grant funding from Janssen-Cilag, AstraZeneca, Eli Lilly, Novartis, and
593 Pfizer; honoraria for consultancy and teaching from Janssen-Cilag, Eli Lilly, Pfizer, AstraZeneca,
594 Roche, Bristol Myers Squibb, and Lundbeck. BN was supported by an NHMRC Senior Research
595 Fellowship (1137687) and a University of Melbourne Dame Kate Campbell Fellowship. This work
596 was supported by the computational infrastructure provided by the MASSIVE HPC facility
597 (www.massive.org.au).

598

599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647

References

- 1 Gur, R. E., Turetsky, B. I., Bilker, W. B. & Gur, R. C. Reduced Gray Matter Volume in Schizophrenia. *Archives of General Psychiatry* **56**, 905-911, doi:10.1001/archpsyc.56.10.905 (1999).
- 2 Haijma, S. V. *et al.* Brain Volumes in Schizophrenia: A Meta-Analysis in Over 18 000 Subjects. *Schizophrenia Bulletin* **39**, 1129-1138, doi:10.1093/schbul/sbs118 (2013).
- 3 Steen, R. G., Mull, C., McClure, R., Hamer, R. M. & Lieberman, J. A. Brain volume in first-episode schizophrenia. *British Journal of Psychiatry* **188**, 510-518, doi:10.1192/bjp.188.6.510 (2006).
- 4 van Erp, T. G. M. *et al.* Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. *Biological Psychiatry* **84**, 644-654, doi:10.1016/j.biopsych.2018.04.023 (2018).
- 5 van Erp, T. G. M. *et al.* Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. *Molecular Psychiatry* **21**, 547-553, doi:10.1038/mp.2015.63 (2016).
- 6 Gupta, C. N. *et al.* Patterns of Gray Matter Abnormalities in Schizophrenia Based on an International Mega-analysis. *Schizophrenia Bulletin* **41**, 1133-1142, doi:10.1093/schbul/sbu177 (2015).
- 7 Vieira, S. *et al.* Neuroanatomical abnormalities in first-episode psychosis across independent samples: a multi-centre mega-analysis. *Psychological Medicine* **51**, 340-350, doi:10.1017/s0033291719003568 (2021).
- 8 Pantelis, C. *et al.* Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. *The Lancet* **361**, 281-288, doi:10.1016/S0140-6736(03)12323-9 (2003).
- 9 Vita, A., De Peri, L., Deste, G. & Sacchetti, E. Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. *Translational Psychiatry* **2**, e190-e190, doi:10.1038/tp.2012.116 (2012).
- 10 Akudjedu, T. N. *et al.* Progression of neuroanatomical abnormalities after first-episode of psychosis: A 3-year longitudinal sMRI study. *Journal of Psychiatric Research* **130**, 137-151, doi:10.1016/j.jpsychires.2020.07.034 (2020).
- 11 Olabi, B. *et al.* Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. *Biological Psychiatry* **70**, 88-96, doi:10.1016/j.biopsych.2011.01.032 (2011).
- 12 Andreasen, N. C. *et al.* Progressive Brain Change in Schizophrenia: A Prospective Longitudinal Study of First-Episode Schizophrenia. *Biological psychiatry* **70**, 672-679, doi:10.1016/j.biopsych.2011.05.017 (2011).
- 13 Chopra, S. *et al.* Differentiating the Effect of Medication and Illness on Brain Volume Reductions in First-Episode Psychosis: A Longitudinal, Randomized, Triple-blind, Placebo-controlled MRI study. *medRxiv* (2020).
- 14 Liloia, D. *et al.* Updating and characterizing neuroanatomical markers in high-risk subjects, recently diagnosed and chronic patients with schizophrenia: A revised coordinate-based meta-analysis. *Neuroscience & Biobehavioral Reviews* **123**, 83-103 (2021).
- 15 Bora, E. *et al.* Neuroanatomical abnormalities in schizophrenia: A multimodal voxelwise meta-analysis and meta-regression analysis. *Schizophrenia Research* **127**, 46-57, doi:10.1016/j.schres.2010.12.020 (2011).

- 648 16 Fornito, A., Yücel, M., Patti, J., Wood, S. J. & Pantelis, C. Mapping grey matter
649 reductions in schizophrenia: An anatomical likelihood estimation analysis of voxel-
650 based morphometry studies. *Schizophrenia Research* **108**, 104-113,
651 doi:10.1016/j.schres.2008.12.011 (2009).
- 652 17 Del Re, E. C. *et al.* Anterior-posterior axis of hippocampal subfields across
653 psychoses: A B-SNIP study. *Biomarkers in Neuropsychiatry* **5**, 100037,
654 doi:<https://doi.org/10.1016/j.bionps.2021.100037> (2021).
- 655 18 Sporns, O., Tononi, G. & Kötter, R. The Human Null_{rewire}: A Structural Description of
656 the Human Brain. *PLOS Computational Biology* **1**, e42,
657 doi:10.1371/journal.pcbi.0010042 (2005).
- 658 19 Raj, A. & Powell, F. Models of Network Spread and Network Degeneration in Brain
659 Disorders. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging* **3**, 788-
660 797, doi:10.1016/j.bpsc.2018.07.012 (2018).
- 661 20 Fornito, A., Zalesky, A. & Breakspear, M. The connectomics of brain disorders.
662 doi:10.1038/nrn3901 (2015).
- 663 21 Seeley, W. W., Crawford, R. K., Zhou, J., Miller, B. L. & Greicius, M. D.
664 Neurodegenerative diseases target large-scale human brain networks. *Neuron* **62**, 42-
665 52 (2009).
- 666 22 Zhou, J., Gennatas, E. D., Kramer, J. H., Miller, B. L. & Seeley, W. W. Predicting
667 regional neurodegeneration from the healthy brain functional connectome. *Neuron* **73**,
668 1216-1227 (2012).
- 669 23 Raj, A., Kuceyeski, A. & Weiner, M. A network diffusion model of disease
670 progression in dementia. *Neuron* **73**, 1204-1215, doi:10.1016/j.neuron.2011.12.040
671 (2012).
- 672 24 Shafiei, G. *et al.* Network structure and transcriptomic vulnerability shape atrophy in
673 frontotemporal dementia. *Brain*, doi:10.1093/brain/awac069 (2022).
- 674 25 Di Biase, M. A. *et al.* Linking Cortical and Connectional Pathology in Schizophrenia.
675 *Schizophr Bull* **45**, 911-923, doi:10.1093/schbul/sby121 (2019).
- 676 26 Wannan, C. M. J. *et al.* Evidence for Network-Based Cortical Thickness Reductions
677 in Schizophrenia. *American Journal of Psychiatry*, appi.ajp.2019.18040380,
678 doi:10.1176/appi.ajp.2019.18040380 (2019).
- 679 27 Cauda, F. *et al.* The morphometric co-atrophy networking of schizophrenia, autistic
680 and obsessive spectrum disorders. *Hum Brain Mapp* **39**, 1898-1928,
681 doi:10.1002/hbm.23952 (2018).
- 682 28 Jiang, Y. *et al.* Antipsychotics effects on network-level reconfiguration of cortical
683 morphometry in first-episode schizophrenia. *medRxiv*, 2021.2001.2017.21249965,
684 doi:10.1101/2021.01.17.21249965 (2021).
- 685 29 Hettwer, M. *et al.* Coordinated cortical thickness alterations across six
686 neurodevelopmental and psychiatric disorders. *Nature Communications* **13**, 1-14
687 (2022).
- 688 30 Cauda, F. *et al.* Brain structural alterations are distributed following functional,
689 anatomic and genetic connectivity. *Brain* **141**, 3211-3232 (2018).
- 690 31 Shafiei, G. *et al.* Spatial patterning of tissue volume loss in schizophrenia reflects
691 brain network architecture. *Biological psychiatry* **87**, 727-735 (2020).
- 692 32 Chopra, S. *et al.* Functional connectivity in antipsychotic-treated and antipsychotic-
693 naive patients with first-episode psychosis and low risk of self-harm or aggression: a
694 secondary analysis of a randomized clinical trial. *JAMA psychiatry* **78**, 994-1004
695 (2021).

- 696 33 Francey, S. M. *et al.* Psychosocial Intervention With or Without Antipsychotic
697 Medication for First-Episode Psychosis: A Randomized Noninferiority Clinical Trial.
698 *Schizophrenia Bulletin Open* **1**, doi:10.1093/schizbullopen/sgaa015 (2020).
- 699 34 Lewandowski, K. E., Bouix, S., Ongur, D. & Shenton, M. E. Neuroprogression across
700 the early course of psychosis. *Journal of psychiatry and brain science* **5** (2020).
- 701 35 Bustillo, J. R. *et al.* Glutamatergic and neuronal dysfunction in gray and white matter:
702 a spectroscopic imaging study in a large schizophrenia sample. *Schizophrenia bulletin*
703 **43**, 611-619 (2017).
- 704 36 Çetin, M. S. *et al.* Thalamus and posterior temporal lobe show greater inter-network
705 connectivity at rest and across sensory paradigms in schizophrenia. *Neuroimage* **97**,
706 117-126, doi:10.1016/j.neuroimage.2014.04.009 (2014).
- 707 37 Esteban, O. *et al.* MRIQC: Advancing the automatic prediction of image quality in
708 MRI from unseen sites. *PLOS ONE* **12**, e0184661, doi:10.1371/journal.pone.0184661
709 (2017).
- 710 38 Gaser, C. & Dahnke, R. CAT - A Computational Anatomy Toolbox for the Analysis
711 of Structural MRI Data. *HBM*, 336-348 (2016).
- 712 39 Ashburner, J. *et al.* SPM12 manual. *Wellcome Trust Centre for Neuroimaging*,
713 *London, UK* **2464** (2014).
- 714 40 Schwarz, D. & Kašpárek, T. Comparison of Two Methods for Automatic Brain
715 Morphometry Analysis. *Radioengineering* **20** (2011).
- 716 41 Guillaume, B., Hua, X., Thompson, P. M., Waldorp, L. & Nichols, T. E. Fast and
717 accurate modelling of longitudinal and repeated measures neuroimaging data.
718 *NeuroImage* **94**, 287-302, doi:10.1016/j.neuroimage.2014.03.029 (2014).
- 719 42 Schaefer, A. *et al.* Local-Global Parcellation of the Human Cerebral Cortex from
720 Intrinsic Functional Connectivity MRI. *Cerebral Cortex (New York, N.Y.: 1991)* **28**,
721 3095-3114, doi:10.1093/cercor/bhx179 (2018).
- 722 43 Tian, Y., Margulies, D. S., Breakspear, M. & Zalesky, A. Topographic organization
723 of the human subcortex unveiled with functional connectivity gradients. *Nature*
724 *Neuroscience* **23**, 1421-1432, doi:10.1038/s41593-020-00711-6 (2020).
- 725 44 Murphy, K. & Fox, M. D. Towards a consensus regarding global signal regression for
726 resting state functional connectivity MRI. *Neuroimage* **154**, 169-173,
727 doi:10.1016/j.neuroimage.2016.11.052 (2017).
- 728 45 Aquino, K. M., Fulcher, B. D., Parkes, L., Sabarodien, K. & Fornito, A. Identifying
729 and removing widespread signal deflections from fMRI data: Rethinking the global
730 signal regression problem. *Neuroimage* **212**, 116614 (2020).
- 731 46 Betzel, R. F. & Bassett, D. S. Specificity and robustness of long-distance connections
732 in weighted, interareal connectomes. *Proceedings of the National Academy of*
733 *Sciences*, 201720186, doi:10.1073/PNAS.1720186115 (2018).
- 734 47 Raj, A., Kuceyeski, A. & Weiner, M. A network diffusion model of disease
735 progression in dementia. *Neuron* **73**, 1204-1215, doi:10.1016/j.neuron.2011.12.040
736 (2012).
- 737 48 Raj, A. *et al.* Network diffusion model of progression predicts longitudinal patterns of
738 atrophy and metabolism in Alzheimer's disease. *Cell reports* **10**, 359-369 (2015).
- 739 49 Pandya, S. *et al.* Predictive model of spread of Parkinson's pathology using network
740 diffusion. *NeuroImage* **192**, 178-194 (2019).
- 741 50 Carletti, F. *et al.* Alterations in White Matter Evident Before the Onset of Psychosis.
742 *Schizophrenia Bulletin* **38**, 1170-1179, doi:10.1093/schbul/sbs053 (2012).
- 743 51 Di Biase, M. A. *et al.* White matter changes in psychosis risk relate to development
744 and are not impacted by the transition to psychosis. *Molecular Psychiatry*,
745 doi:10.1038/s41380-021-01128-8 (2021).

- 746 52 Kraguljac, N. V. *et al.* White matter integrity, duration of untreated psychosis, and
747 antipsychotic treatment response in medication-naïve first-episode psychosis patients.
748 *Molecular Psychiatry* **26**, 5347-5356, doi:10.1038/s41380-020-0765-x (2021).
- 749 53 Kelly, S. *et al.* Widespread white matter microstructural differences in schizophrenia
750 across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working
751 Group. *Molecular psychiatry* **23**, 1261-1269 (2018).
- 752 54 Bradshaw, N. J. & Korth, C. Protein misassembly and aggregation as potential
753 convergence points for non-genetic causes of chronic mental illness. *Molecular*
754 *psychiatry* **24**, 936-951 (2019).
- 755 55 Guo, J. L. & Lee, V. M. Cell-to-cell transmission of pathogenic proteins in
756 neurodegenerative diseases. *Nature medicine* **20**, 130-138 (2014).
- 757 56 Yao, L. *et al.* White matter deficits in first episode schizophrenia: An activation
758 likelihood estimation meta-analysis. *Progress in Neuro-Psychopharmacology and*
759 *Biological Psychiatry* **45**, 100-106, doi:<https://doi.org/10.1016/j.pnpbp.2013.04.019>
760 (2013).
- 761 57 Arnatkeviciute, A. *et al.* Genetic influences on hub connectivity of the human
762 connectome. *Nature Communications* **12**, 4237, doi:10.1038/s41467-021-24306-2
763 (2021).
- 764 58 Fornito, A., Arnatkevičiūtė, A. & Fulcher, B. D. Bridging the Gap between Null_{rewire}
765 and Transcriptome. *Trends Cogn Sci* **23**, 34-50, doi:10.1016/j.tics.2018.10.005
766 (2019).
- 767 59 Hansen, J. Y. *et al.* Mapping neurotransmitter systems to the structural and functional
768 organization of the human neocortex. *bioRxiv*, 2021.2010.2028.466336,
769 doi:10.1101/2021.10.28.466336 (2022).
- 770 60 Hansen, J. Y. *et al.* Local molecular and global connectomic contributions to cross-
771 disorder cortical abnormalities. *Nature communications* **13**, 1-17 (2022).
- 772 61 Lipska, B. K. & Weinberger, D. R. A neurodevelopmental model of schizophrenia:
773 neonatal disconnection of the hippocampus. *Neurotoxicity research* **4**, 469-475
774 (2002).
- 775 62 Rosso, I. M. *et al.* Obstetric risk factors for early-onset schizophrenia in a Finnish
776 birth cohort. *American Journal of Psychiatry* **157**, 801-807 (2000).
- 777 63 Bearden, C. E., Meyer, S. E., Loewy, R. L., Niendam, T. A. & Cannon, T. D. The
778 neurodevelopmental model of schizophrenia: Updated. *Developmental*
779 *Psychopathology: Volume Three: Risk, Disorder, and Adaptation*, 542-569 (2015).
- 780 64 Osimo, E. F., Beck, K., Reis Marques, T. & Howes, O. D. Synaptic loss in
781 schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA
782 measures. *Molecular Psychiatry* **24**, 549-561, doi:10.1038/s41380-018-0041-5
783 (2019).
- 784 65 Harrison, P. J. & Eastwood, S. L. Neuropathological studies of synaptic connectivity
785 in the hippocampal formation in schizophrenia. *Hippocampus* **11**, 508-519 (2001).
- 786 66 Radhakrishnan, R. *et al.* In vivo evidence of lower synaptic vesicle density in
787 schizophrenia. *Molecular Psychiatry*, doi:10.1038/s41380-021-01184-0 (2021).
- 788 67 Onwordi, E. C. *et al.* Synaptic density marker SV2A is reduced in schizophrenia
789 patients and unaffected by antipsychotics in rats. *Nature Communications* **11**, 246,
790 doi:10.1038/s41467-019-14122-0 (2020).
- 791 68 Weinberger, D. R. Implications of Normal Brain Development for the Pathogenesis of
792 Schizophrenia. *Archives of General Psychiatry* **44**, 660-669,
793 doi:10.1001/archpsyc.1987.01800190080012 (1987).

- 794 69 Lodge, D. J. & Grace, A. A. Hippocampal dysregulation of dopamine system function
795 and the pathophysiology of schizophrenia. *Trends in pharmacological sciences* **32**,
796 507-513 (2011).
- 797 70 Grace, A. Dopamine system dysregulation by the hippocampus: implications for the
798 pathophysiology and treatment of schizophrenia. *Neuropharmacology* **62**, 1342-1348
799 (2012).
- 800 71 Modinos, G., Allen, P., Grace, A. A. & McGuire, P. Translating the MAM model of
801 psychosis to humans. *Trends Neurosci* **38**, 129-138, doi:10.1016/j.tins.2014.12.005
802 (2015).
- 803 72 Sabaroedin, K., Tiego, J. & Fornito, A. Circuit-based approaches to understanding
804 corticostriothalamic dysfunction across the psychosis continuum. *Biological*
805 *Psychiatry* (2022).
- 806 73 Lieberman, J. *et al.* Hippocampal dysfunction in the pathophysiology of
807 schizophrenia: a selective review and hypothesis for early detection and intervention.
808 *Molecular psychiatry* **23**, 1764-1772 (2018).
- 809 74 Schobel, S. A. *et al.* Imaging patients with psychosis and a mouse model establishes a
810 spreading pattern of hippocampal dysfunction and implicates glutamate as a driver.
811 *Neuron* **78**, 81-93 (2013).
- 812 75 Vidal, C. N. *et al.* Dynamically Spreading Frontal and Cingulate Deficits Mapped in
813 Adolescents With Schizophrenia. *Archives of General Psychiatry* **63**, 25-34,
814 doi:10.1001/archpsyc.63.1.25 (2006).
- 815 76 Thompson, P. M. *et al.* Mapping adolescent brain change reveals dynamic wave of
816 accelerated gray matter loss in very early-onset schizophrenia. *Proceedings of the*
817 *National Academy of Sciences* **98**, 11650-11655, doi:10.1073/pnas.201243998 (2001).
- 818 77 Sun, D. *et al.* Progressive Brain Structural Changes Mapped as Psychosis Develops in
819 'At Risk' Individuals. *Schizophrenia research* **108**, 85-92,
820 doi:10.1016/j.schres.2008.11.026 (2009).
- 821 78 Sun, D. *et al.* Brain surface contraction mapped in first-episode schizophrenia: a
822 longitudinal magnetic resonance imaging study. *Molecular Psychiatry* **14**, 976-986,
823 doi:10.1038/mp.2008.34 (2009).
- 824 79 Jalbrzikowski, M. Association of Structural Magnetic Resonance Imaging Measures
825 With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis:
826 An ENIGMA Working Group Mega-analysis. *JAMA Psychiatry* **78**, 753-766,
827 doi:10.1001/jamapsychiatry.2021.0638 (2021).
- 828 80 Cannon, T. D. *et al.* Progressive reduction in cortical thickness as psychosis develops:
829 a multisite longitudinal neuroimaging study of youth at elevated clinical risk. *Biol*
830 *Psychiatry* **77**, 147-157, doi:10.1016/j.biopsych.2014.05.023 (2015).
- 831 81 Chung, Y. *et al.* Cortical abnormalities in youth at clinical high-risk for psychosis:
832 Findings from the NAPLS2 cohort. *NeuroImage: Clinical* **23**, 101862,
833 doi:<https://doi.org/10.1016/j.nicl.2019.101862> (2019).
- 834 82 Del Re, E. C. *et al.* Baseline Cortical Thickness Reductions in Clinical High Risk for
835 Psychosis: Brain Regions Associated with Conversion to Psychosis Versus Non-
836 Conversion as Assessed at One-Year Follow-Up in the Shanghai-At-Risk-for-
837 Psychosis (SHARP) Study. *Schizophrenia Bulletin* **47**, 562-574 (2021).
- 838 83 Collins, M. A. *et al.* Accelerated cortical thinning precedes and predicts conversion to
839 psychosis: The NAPLS3 longitudinal study of youth at clinical high-risk. *Mol*
840 *Psychiatry*, doi:10.1038/s41380-022-01870-7 (2022).
- 841 84 Cropley, V. L. *et al.* Accelerated Gray and White Matter Deterioration With Age in
842 Schizophrenia. *Am J Psychiatry* **174**, 286-295, doi:10.1176/appi.ajp.2016.16050610
843 (2017).

- 844 85 Gogtay, N., Vyas, N. S., Testa, R., Wood, S. J. & Pantelis, C. Age of onset of
845 schizophrenia: perspectives from structural neuroimaging studies. *Schizophr Bull* **37**,
846 504-513, doi:10.1093/schbul/sbr030 (2011).
- 847 86 Wolfers, T. *et al.* Mapping the Heterogeneous Phenotype of Schizophrenia and
848 Bipolar Disorder Using Normative Models. *JAMA Psychiatry*,
849 doi:10.1001/jamapsychiatry.2018.2467 (2018).
- 850 87 Lv, J. *et al.* Individual deviations from normative models of brain structure in a large
851 cross-sectional schizophrenia cohort. *Molecular Psychiatry* **26**, 3512-3523,
852 doi:10.1038/s41380-020-00882-5 (2021).
- 853 88 Segal, A. *et al.* Regional, circuit, and network heterogeneity of brain abnormalities in
854 psychiatric disorders. *medRxiv*, 2022.2003.2007.22271986,
855 doi:10.1101/2022.03.07.22271986 (2022).
- 856 89 Leucht, S. *et al.* Clinical implications of Brief Psychiatric Rating Scale scores. *British*
857 *Journal of Psychiatry* **187**, 366-371, doi:10.1192/bjp.187.4.366 (2005).
- 858 90 Henry, L. P. *et al.* The EPPIC Follow-Up Study of First-Episode Psychosis: Longer-
859 Term Clinical and Functional Outcome 7 Years After Index Admission. *The Journal*
860 *of Clinical Psychiatry* **71**, 716-728, doi:10.4088/JCP.08m04846yel (2010).
861